Skip to main content
Home > Week in Review > Deals

Chronological Index of BioCentury, Week in Review: Deals

BioCentury, Week in Review Current Issue
  • Adaptive Biotechnologies, Bristol-Myers deal

    Adaptive Biotechnologies Corp., Seattle, Wash. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer, Pharmacogenetics Adaptive and Bristol-Myers partnered to discover biomarkers that indicate response to…

    Published on 5/20/2013
  • Altus Formulation Inc., Halo Pharmaceutical Inc. deal

    Altus Formulation Inc., Montreal, Quebec Halo Pharmaceutical Inc., Whippany, N.J. Business: Supply/Service Drug development and commercial manufacturing services company Halo acquired an undisclosed minority stake in …

    Published on 5/20/2013
  • Alvine, AbbVie deal

    Alvine Pharmaceuticals Inc., San Carlos, Calif. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Autoimmune Alvine granted AbbVie an exclusive option to acquire the company or its ALV003, which is in Phase II testing to…

    Published on 5/20/2013
  • American CryoStem, Rutgers University deal

    American CryoStem Corp. (OTCQB:CRYO), Red Bank, N.J. Rutgers University, Newark, N.J. Business: Dermatology, Gene/Cell therapy American CryoStem provided researchers at the university access to autologous adipose-…

    Published on 5/20/2013
  • Aveo Pharmaceuticals, J&J deal

    Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Cambridge, Mass. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer, Pharmacogenetics Aveo disclosed in a 10-Q filing that Johnson & Johnson's Janssen Biotech Inc…

    Published on 5/20/2013
  • Bayer, California Institute for Quantitative Biosciences (QB3) deal

    Bayer AG (Xetra:BAYN), Leverkusen, Germany California Institute for Quantitative Biosciences (QB3), San Francisco, Calif. Business: Pharmaceuticals Bayer's Bayer Healthcare LLC subsidiary partnered with QB3 under a …

    Published on 5/20/2013
  • Calypso Biotech, iDD Biotech deal

    Calypso Biotech S.A., Plan-les-Ouates, Switzerland iDD Biotech, Dardilly, France Business: Autoimmune iDD Biotech granted Calypso exclusive, worldwide rights to CALY-002, a humanized mAb, to treat refractory celiac …

    Published on 5/20/2013
  • Cempra, Toyama deal

    Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C. Toyama Chemical Co. Ltd. (Tokyo:4518), Tokyo, Japan Business: Infectious Cempra granted Toyama exclusive rights to develop and commercialize solithromycin in Japan. The …

    Published on 5/20/2013
  • Clovis, Cancer Research UK deal

    Clovis Oncology Inc. (NASDAQ:CLVS), Boulder Colo. Cancer Research UK, London, U.K. Business: Cancer Cancer Research UK granted Clovis access to clinical data from an ongoing, U.K Phase II trial evaluating rucaparib …

    Published on 5/20/2013
  • D. Western, Wakamoto Pharmaceutical deal

    D. Western Therapeutics Institute Inc. (JASDAQ:4576), Nagoyashi, Japan Wakamoto Pharmaceutical Co. Ltd. (Tokyo:4512), Tokyo, Japan Business: Ophthalmic In March, D. Western granted Wakamoto exclusive rights in Japan to …

    Published on 5/20/2013
  • DBV, Stallergenes deal

    DBV Technologies (Euronext:DBV), Bagneux, France Stallergenes S.A. (Euronext:GENP), Antony, France Business: Inflammation, Drug delivery Stallergenes and DBV partnered to develop immunotherapies for respiratory …

    Published on 5/20/2013
  • DxNA, PathoGene deal

    DxNA LLC, St. George, Utah PathoGene LLC, Flagstaff, Ariz. Business: Diagnostic DxNA acquired from PathoGene exclusive, worldwide rights to use unit dose platform applications of multiplex Staphylococcus MRSA+ assay on …

    Published on 5/20/2013
  • Elan, Theravance, GlaxoSmithKline deal

    Elan Corp. plc (NYSE:ELN), Dublin, Ireland Theravance Inc. (NASDAQ:THRX), South San Francisco, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Pulmonary Elan said it will pay $1 billion in cash to…

    Published on 5/20/2013
  • Evotec, Harvard University deal

    Evotec AG (Xetra:EVT), Hamburg, Germany Harvard University, Cambridge, Mass. Business: Infectious Evotec partnered with the university to discover and develop small molecule inhibitors of peptidoglycan biosynthesis. …

    Published on 5/20/2013
  • Full Spectrum Genetics deal

    Full Spectrum Genetics Inc., South San Francisco, Calif. Business: Antibodies, Supply/Service Full Spectrum said it received a milestone payment from an undisclosed pharma under a 2012 deal to engineer and analyze …

    Published on 5/20/2013
  • Galenica, Helsinn deal

    Galenica Ltd. (SIX:GALN), Bern, Switzerland Helsinn Healthcare S.A., Pazzallo-Lugano, Switzerland Business: Gastrointestinal Helsinn granted Galenica's Vifor Pharma Ltd. specialty pharma business an exclusive license to…

    Published on 5/20/2013
  • Genor Biopharma, RuiYi deal

    Genor Biopharma Co. Ltd., Shanghai, China RuiYi Inc., La Jolla, Calif. Business: Autoimmune, Cancer RuiYi granted Genor exclusive rights to develop and commercialize RYI-008 (ARGX-109) in China. RYI-008, an anti-IL-6 …

    Published on 5/20/2013
  • Immunomedics, Takeda deal

    Immunomedics Inc. (NASDAQ:IMMU), Morris Plains, N.J. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Autoimmune Immunomedics disclosed in its fiscal 3Q13 earnings for the period ended March 31 that …

    Published on 5/20/2013
  • Instem plc, Logos Holdings Ltd. deal

    Instem plc (LSE:INS), Staffordshire, U.K. Logos Holdings Ltd., London, U.K. Business: Other IT solutions company Instem acquired Logos Holdings for 550,000 ($844,910) in cash up front, with up to an additional 4.5 …

    Published on 5/20/2013
  • Ion Beam Applications deal

    Ion Beam Applications S.A. (Euronext:IBAB), Louvain-la-Neuve, Belgium Business: Genomics, Diagnostic Ion Beam Applications signed a term sheet with a European private equity firm to sell Ion Beam's Cisbio Bioassays S.A.…

    Published on 5/20/2013
  • MDxHealth, Merck KGaA deal

    MDxHealth S.A. (Euronext:MDXH), Liege, Belgium Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Pharmacogenetics MDxHealth disclosed in its 1Q13 earnings that Merck terminated the 2011 portion of an expanded 2008 …

    Published on 5/20/2013
  • NicOx, Ferrer deal

    NicOx S.A. (Euronext:COX), Sophia-Antipolis, France Grupo Ferrer Internacional S.A., Barcelona, Spain Business: Dermatology NicOx disclosed in its 1Q13 earnings that the companies terminated an amended 2004 deal under …

    Published on 5/20/2013
  • Oxford BioDynamics, Agency for Science, Technology and Research (A*STAR) deal

    Oxford BioDynamics Ltd., Oxford, U.K. Agency for Science, Technology and Research (A*STAR), Singapore Business: Genomics A*STAR's Genome Institute of Singapore and Oxford BioDynamics partnered to identify epigenetic …

    Published on 5/20/2013
  • Quintiles, Merck KGaA deal

    Quintiles Transnational Corp. (NYSE:Q), Research Triangle Park, N.C. Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Supply/Service The companies signed a five-year deal under which Quintiles will be the sole …

    Published on 5/20/2013
  • Roche, California Institute for Quantitative Biosciences (QB3) deal

    Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland California Institute for Quantitative Biosciences (QB3), San Francisco, Calif. Business: Pharmaceuticals Roche partnered with QB3 to launch the Collaborative Startups …

    Published on 5/20/2013

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?